ClinicalTrials.gg
RecruitingNCT04143516Updated Nov 3, 2026

Tissue Analysis After Tumor Ablation for Liver Metastases Leading to Immediate Retreatment

A Phase 2/3 interventional study of [18-F]- FDG - PET and Tumor ablation (TA) in Liver Metastases, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Memorial Sloan Kettering Cancer Center · Phase 2/3, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Oct 2019; still recruiting 7 years later.
Updated Nov 3, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 61 studies in Neoplasm Metastasis by Memorial Sloan Kettering Cancer Center — 13 open to participants now, 27 under way, 1 of them phase 3. Neoplasm Metastasis · Memorial Sloan Kettering Cancer Center.

Planned enrollment
Largest of 50
200 · median 37
Started
2019
with 1 other
Phase 2/3
Only one
of the 61
Primary completion
2027-10
later than 17 of 26 live
Registered
42nd of 61
by date

Among the 61 studies in Neoplasm Metastasis by Memorial Sloan Kettering Cancer Center, this one has the largest planned enrollment of the 50 interventional ones that give a count, is one of 2 that started in 2019, is the only one in phase 2/3, reaches primary completion later than 17 of the 26 other live ones, and was the 42nd registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

13 of the 61 studies in Neoplasm Metastasis by Memorial Sloan Kettering Cancer Center are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Neoplasm Metastasis by Memorial Sloan Kettering Cancer Center, or all of them as a file.
02

Study summary

This study will see whether collecting and analyzing needle biopsy samples from cancer liver metastases after a tumor ablation procedure will be able to identify cancer cells that are still alive. The results of these biopsies could help determine the next treatment for your cancer, but the biopsies could cause side effects.

03

Conditions studied

  • Liver Metastases

Browse trials for

Keywords

  • Optimizing Tumor Ablation
  • Rapid Tissue Analysis
  • Metabolic Imaging Biomarker Validation
  • Predictive Genetic Signatures
  • 19-332
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of liver from various primary tumors
  • Confined liver disease or limited extrahepatic disease stable/controlled for at least 4 months (extrahepatic disease amenable to treatment is allowed)
  • Lesions of ≤3 cm in maximum diameter
  • At least one FDG-avid lesion to be treated***
  • \< 1.5*
  • count ≥ 50,000

Exclusion criteria

Exclusion Criteria:

  • Age \< 18
  • Less than 5 mm distance to a structure (GI or biliary tract), that cannot be protected from ablation injury with technical modifications such as hydro or air dissection
  • > 1.5 that cannot be corrected with fresh frozen plasma **
  • count of \<50,000 that cannot be corrected with transfusion
  • More than 3 tumors in the liver
  • More than 5 tumors of extrahepatic disease (including mediastinal nodes and pulmonary nodules, abdominal or other lymph nodes, and bone )
  • Presence of any peritoneal Carcinomatosis

    • For patients on Coumadin, general clinical guidelines for IR ablation will be followed.

      • For patients with no FDG-PET avid tumors aim 2 of the protocol will not be assessed
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Patients with Liver Metastases

    The standard of care tumor ablation procedure, post-ablation biopsies and pre- and post-ablation PET scans. If the PET scan is positive (shows areas of cancer in the treated metastases), study participants will undergo additional needle biopsies of the positive areas on the scan. If the biopsies show areas of cancer cells that are still alive, the participants will be immediately retreated with a second ablation procedure.

    Diagnostic Test: [18-F]- FDG - PET · Procedure: Tumor ablation (TA) · Diagnostic Test: PET/CT Scan

Interventions

  • Diagnostic test[18-F]- FDG - PET

    Patients will undergo a limited non-contrast CT and first injection PET to localize the lesion

  • ProcedureTumor ablation (TA)

    Standard ablation with the intent to create a radius of ablation at least 10 mm larger than the largest lesion diameter in order to achieve a minimum of 5 mm ablation margin around the tumor. Any radiographically-identified and biopsy-confirmed residual tumor will be treated on site with immediate ablation. This repeat ablation is not standard of care but will be performed as described for the initial ablation (in the same procedure session) and follow up will be resumed.

  • Diagnostic testPET/CT Scan

    Eligible patients will undergo PET/CT -guided tumor ablation as per standard IR guidelines. All patients will undergo PET/CT again, within approximately 6 weeks (+/- 2 weeks) of tumor ablation to evaluate for CN in the target tumor(s) or any sign of residual tissue enhancement, representing viable residual tumor and incomplete treatment.

06

What researchers measure

Primary outcomes

  1. Tumor response

    will be measured according to RECIST and PERCIST 1.0. The first CT and PET scan taken after ablation will be considered the new baseline for subsequent comparisons and measurements.

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
    Recruiting
    • Constantinos Sofocleous, MD, PhD · Contact212-639-3379
    • Efsevia Vakiani, MD,PhD · Contact646-888-3060
    • Constantinos Sofocleous, MD,PhD · Principal investigator
08

References and documents

Publications

  • Dimopoulos MP, Sotirchos VS, Vakiani E, Sigel C, Petre EN, Kunin H, Kirov AS, Gonen M, Wei A, Soares K, Solomon SB, Schwartz LH, Sofocleous CT. Optimizing Colorectal Liver Metastasis Ablation through Metabolic Imaging, Margin Assessment, and Biopsy (The OPTABLATE Prospective Trial). Radiology. 2026 Mar;318(3):e250864. doi: 10.1148/radiol.250864. PubMed 41874299 ↗

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2019 (actual). Primary completion is estimated for Oct 2027, 96 months after the start.

Of 27 phase 2/3 interventional studies under Neoplasm Metastasis, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 98. This study's planned 96 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion Oct 2026 → Oct 2027 and completion Oct 2026 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2019
First posted
Oct 29, 2019
StartActual
Oct 25, 2019
Primary completionEst.
Oct 2027was Oct 2026
CompletionEst.
Oct 2027was Oct 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 2026→Oct 2027
Nov 3, 2026
Study completion
Oct 2026→Oct 2027
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Primary completion Oct 2026→Oct 2027
    Study completion Oct 2026→Oct 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04143516
Responsible party
Sponsor
First posted
Oct 29, 2019
Start date
Oct 25, 2019
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Nov 3, 2026

Study contacts

Constantinos Sofocleous, MD, PhD
Contact
sofoclec@mskcc.org
212-639-3379
Efsevia Vakiani, MD,PhD
Contact
646-888-3060
Constantinos Sofocleous, MD, PhD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion